| Literature DB >> 30099402 |
Saurab Sharma1,2, Mark P Jensen3, G Lorimer Moseley4, J Haxby Abbott2.
Abstract
INTRODUCTION: Low back pain (LBP) is the leading cause of years lived with disability in Nepal and elsewhere. Management of LBP that is evidence-based, easily accessible, cost-effective and culturally appropriate is desirable. The primary aim of this feasibility study is to determine if it is feasible to conduct a full randomised clinical trial evaluating the effectiveness of pain education as an intervention for individuals with LBP in Nepal, relative to guideline-based physiotherapy treatment. The findings of the study will inform the planning of a full clinical trial and if any modifications are required to the protocol before undertaking a full trial. METHODS/ANALYSIS: This protocol describes an assessor-blinded feasibility clinical trial investigating feasibility of the pain education intervention in patients with non-specific LBP in a physiotherapy hospital in Kathmandu, Nepal. Forty patients with LBP will be randomly allocated to either pain education or guideline-based physiotherapy treatment (control). Outcomes will be assessed at baseline and at a 1 week post-treatment. The primary outcomes are related to feasibility, including: (1) participant willingness to participate in a randomised clinical trial, (2) feasibility of assessor blinding, (3) eligibility and recruitment rates, (4) acceptability of screening procedures and random allocation, (5) possible contamination between the groups, (6) intervention credibility, (7) intervention adherence, (8) treatment satisfaction and (9) difficulty in understanding the interventions being provided. ETHICS/DISSEMINATION: The protocol was approved by Nepal Health Research Council (NHRC; registration number: 422/2017) and University of Otago Human Ethics Committee for Health (registration number: H17/157). The results of the study will be presented at national and international conferences and published in a peer-reviewed journal. TRIAL REGISTRATION NUMBER: NCT03387228; Pre-results. © Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY. Published by BMJ.Entities:
Mesh:
Year: 2018 PMID: 30099402 PMCID: PMC6089285 DOI: 10.1136/bmjopen-2018-022423
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Schedule of enrolment, assessment and interventions
| Timepoint | Study period | ||||
| Enrolment | Allocation | Post allocation | Final Assessment | ||
| −T1 | T0 | T1 | T2 | T3 | |
| Enrolment | |||||
| Eligibility screening | X | ||||
| Explain study procedure/provide participant information sheets | X | ||||
| Informed consent | X | ||||
| Random treatment allocation | X | ||||
| Intervention | |||||
| Experimental intervention (PEG) | X | ||||
| Control group (CG) | X | ||||
| Assessment | |||||
| Baseline descriptive variables | |||||
| Sociodemographic information (age, sex, address, occupation, religion and ethnicity) | X | ||||
| History | |||||
| Pain history (site of pain, duration of pain, continuous or intermittent pain, aggravating and relieving factors) | X | ||||
| Comorbidities | X | ||||
| Feasibility | |||||
| Willingness to participate in a randomised controlled trial | X | ||||
| Acceptability of random allocation to one of the two groups | X | ||||
| Acceptability of intervention session (one session in a week with home treatment programme throughout the week) | X | ||||
| Feasibility of blinding the assessor* | X | ||||
| Eligibility and recruitment rates | X | ||||
| Acceptability of screening procedures* | W | ||||
| Understanding possible contamination between the groups | X | ||||
| Evaluating the credibility of the intervention | X | X | |||
| Adherence to intervention | X | ||||
| Treatment satisfaction | X | ||||
| Difficulty in understanding the treatments | X | ||||
| Secondary outcomes | |||||
| PROMIS Pain interference | X | X | |||
| PROMIS Pain intensity | X | X | |||
| Quality of life | X | X | |||
| PROMIS Sleep disturbance | X | X | |||
| PROMIS Depression | X | X | |||
| GROC | – | X | |||
| PCS | X | X | |||
| CD-RISC-10 | X | X | |||
*Assessed by the therapist providing intervention; all other outcomes are assessed by the blinded outcome assessor.
CD-RISC-10, 10-item Connor-Davidson Resilience Scale; GROC, Global Rating of Change; PCS, Pain Catastrophizing Scale; PROMIS, Patient-Reported Outcome Measurement Information System; T, enrolment time; T, allocation time; T, baseline assessment (before treatment); T, during treatment; T, 1 week post-treatment; W, assessment at the end of every week on Fridays.
How will each primary feasibility objective be assessed?
| Serial Number | Objectives | Measures to assess specific objectives | Statistical analysis |
| 1 | Willingness to participate in a randomised controlled trial | All the consecutive participants presenting at the physiotherapy department will be approached and invited to participate. The number and rate of participants willing versus not willing to participate will be recorded, as well the reasons for not wanting to participate. | Total number of patients not willing to participate will be summed and reasons for non-participation collated. |
| 2 | Feasibility of blinding the assessor | Feasibility of blinding will be assessed by asking the assessor two questions at the end of the follow-up assessment: | The frequency and relative rates of ‘ |
| 3 | Eligibility and recruitment rates | The total number of participants screened, found eligible and recruited will be recorded during the screening and recruitment process. The reasons why the participants were ineligible for study inclusion will be recorded for every participant who did not meet eligibility criteria. Reasons for declining participation will be recorded for every eligible individual who declined participation. Consent rates will also be recorded. | The number of participants screened, who were eligible, who consented to participate, who refused to participate will be computed. The reasons for exclusion and refusal will also be collated. |
| 4 | Acceptability of screening procedures | The lead researcher will interview the physiotherapist(s) screening the potential participants for eligibility by asking the following open-ended question at the end of every week, ‘ | The frequency of difficulties or challenges will be counted. |
| 5 | Acceptability of random allocation to a treatment group | Outcome assessor will ask the participants if random allocation to one of the two treatment groups is acceptable to the participants. Responses will be recorded as ‘Acceptable’, ‘Not acceptable’ or ‘No preference’. | The frequencies of each response will be computed separately for each treatment condition. |
| 6 | Understanding possible contamination between the groups | Contamination between the groups will be assessed by asking all the study participants the following questions at 1 week following treatment: | The frequencies of the participants who responded affirmatively to each question will be computed separately for each treatment condition. |
| 7 | Credibility and acceptability of the interventions | Treatment credibility will be assessed using five questions adapted from Borkovec and Nau. | Mean of the total scores on the credibility scale will be computed separately for each condition. Between-condition differences in creditability will be evaluated using a t-test. |
| 8 | Adherence to the intervention | Adherence to treatment will be assessed by asking the participants in both conditions to maintain a record of daily home treatment that was followed by every participant. The participants will tick mark a box for every day for a total of 5 days between the two assessment time-points to indicate their adherence to prescribed home exercise programme. Additionally, participants will be requested to record any deviation of prescribed home treatment programme (eg, additional visit to the clinic and use of other interventions). Finally, question regarding non-adherence will be asked. | The total number of treatment adherence days will be summed for each treatment condition separately. |
| 9 | Satisfaction of treatment | All the participants in both the conditions will be asked to respond to the Patient Global Assessment of Treatment Satisfaction scale at 1 week following treatment. | Mean treatment satisfaction scores will be computed for each treatment condition separately. Between-condition differences will be evaluated using a t-test. |
| 10 | Difficulty in understanding the information provided by the physiotherapist. | All the participants will be asked about the difficulty in understanding the information provided by the physiotherapist. The question asked will be, ‘ | The differences in the difficulty in understanding the information provided will be compared between the two groups. |
| 11 | Difficulty in understanding the instructions for what to do. | All participants will be asked about the difficulty in understanding the instructions provided by the physiotherapist for what to do at home. The question asked will be, ‘ | Frequencies and rates of each response category will be computed for each group separately. |
| 12 | Adverse events | All participants will be asked about any adverse events after treatment. All responses will be recorded verbatim. | The number of adverse events listed will be computed for each treatment condition separately. The responses will be analysed qualitatively (see text). |
LBP, low back pain.
Secondary outcome measures
| Domain | Name of outcome measure | No. of Items | Response scale | Scoring | Measurement properties of Nepali versions of the scale |
| Pain interference | PROMIS Pain Interference short-form 6b | 6 | 5-point, ordinal | Respondents are asked to rate how much pain interfered with their daily life (eg, enjoyment of life, ability to concentrate and day-to-day activities) in past 7 days on 5-point Likert scales (=‘ |
Good internal consistency (Cronbach’s alpha=0.85). Excellent reliability (ICC=0.80) in a sample of individuals with chronic pain from Nepal. |
| Pain catastrophising | Pain Catastrophizing Scale (PCS) | 13 | 5-point, ordinal | Respondents are asked to indicate the degree or frequency with which they have each catastrophising response listed when they ‘… are experiencing pain’ on a 5-point Likert scale (0=‘ |
Good to excellent internal consistencies: Cronbach’s alpha=0.85–0.93. Excellent test–retest stability (ICC=0.89–0.90). Positive moderate correlations with measures of pain intensity, depression and anxiety in a sample of individuals with chronic pain from Nepal. |
| Patient’s global rating of change | Global Rating of Change | 1 | 1–7, ordinal | Respondents are asked to rate their ‘ | MIC: 1 point change. |
| Quality of life (QOL) | QOL rating scale | 2 | 5-point, ordinal | Respondents are asked to rate their general QOL and general health by responding to the questions: | Not available during the time of protocol writing the study protocol. |
| Pain intensity | PROMIS Pain Intensity short-form 3b | 3 | 5-point, ordinal | Respondents are asked to rate their current pain and their worst and average pain intensity in past 7 days on 5-point Likert scales (1=‘ | Good test–retest reliability (ICC=0.71) in a sample of individuals with chronic pain from Nepal. |
| Sleep disturbance | PROMIS Sleep disturbance short-form 8b | 7* | 5-point, ordinal | Respondents are asked to rate sleep quality items on a 5-point Likert scale. Responses are scored as a T-score that can range from 0 to 100, with a mean of 50 and SD of 10 in the normative sample. | Although the Nepali translation of the 8-item Sleep Disturbance short-form showed poor reliability, removal of one item, improved the test–retest stability to excellent. (ICC=0.78). |
| Depression | PROMIS Emotional Distress- Depression short-form 8b | 8 | 5-point, ordinal | Respondents are asked to indicate the frequency of depressive symptoms in the past 7 days on a 5-point verbal rating scale (1=‘ |
Excellent internal consistency (Cronbach’s alpha=0.93). Excellent test–retest reliability (ICC=0.81) in a sample of individuals with chronic pain from Nepal. |
| Resilience | 10-item Connor Davidson Resilience Scale | 10 | 4-point, ordinal | Respondents are asked to rate each resilience item on a 5-point Likert scale: 0=‘ |
Good to excellent internal consistency (Cronbach’s alpha=0.87–0.90). Excellent test–retest stability (ICC=0.89). SE of measurement=2.42 points. Minimum detectable change=6.72 points. Significant negative and moderate association with the PCS in a sample of individuals with chronic pain from Nepal. |
| Use of pain medications and other pain treatments | – | – | – | Names and dosage of pain medication intake will be recorded by the assessor by asking the research participant via interview. Medications will then be categorised into analgesic type (opioids, non-steroidal anti-inflammatory drugs, sedatives and antiseizure medications), as will the number of days each type of medication is taken. |
No validity data for self-reported analgesic or pain treatment use in Nepali patients available at the time of protocol writing. |
*Only seven items out of eight items will be included, as the measurement properties of the total eight-item was poor, and only after removal of one item, the reliability improved.
ICC, Intraclass Correlation Coefficient; MIC, minimum important change; SE, standard error.
Criteria for feasibility
| Criteria | Full trial is not feasible as designed | Proceed to a full trial without modification in the protocol of the feasibility trial | ||
| Modify the protocol prior to a full trial if… | Action | Monitor the study procedures closely if… | Close monitoring is not required if… | |
| Blinding of assessor | Assessor has a >70% correct guess rate on the group allocation. | Identify ways to improve assessor blinding based on the responses or feedback provided by the assessors. | 70%–90% blinding is found. | <10% incorrect guess to the group allocation. |
| Recruitment rate | ≤1 participant every week | Identify reasons for low participation rates or declining participation. | 2–3 participants recruited every week. | ≥4 participants recruited every week. |
| Attrition rate (in both arms) | >30% total drop-outs at 1 week post-treatment. | Identify possible reasons for drop-outs and ways to improve follow-up participation. | 15%–30% total drop-outs at 1 week post-treatment. | <15% total drop-outs at 1 week post-treatment. ( |
| Feasibility of outcome assessment | >20% missing data on the secondary outcome measures. | Reduce the number of outcome measures. | 10%–20% missing data on the secondary outcome measures. | <10% missing data on the secondary outcome measures. |
| Contamination of intervention | ≥15% contamination between the groups. | Identify reasons for contamination and resolve them. | <15% contamination between the groups. | 0% contamination between the groups. |
| Score on the credibility of treatment scale | Control condition is >0.50 SD credible than pain education group. | Develop a new control condition for the EP trial and pilot test to ensure that its credibility rating is <0.50 SD different from pain education group. | - | The credibility scores of the two conditions are within 0.50 SD units of each other. |
| Adherence to treatment | <50% attend the treatment session after randomisation. | Identify reasons for not attending the treatment session in order to increase attendance in the full trial. | 50%–80% of the participants attend the treatment session. | 80% or more of the participants attend the treatment sessions. |
| Difficulty scale | If ≥50% participants in the experimental group rate pain education as very difficult, very easy, easy or neither easy nor difficult. | Make the intervention a little more challenging if more than half of the participants report 1–3 out of 5 in the difficulty scale, by increasing the depth of the education, by adding more pain biology education content. Whereas if more than half participants report the intervention as very difficult, reduce the complexity. Re-evaluate complexity in a second cohort of at least five participants to ensure appropriate level of difficulty. | - | ≥50% participants in the experimental group rate pain education as a ‘difficult’ intervention (4 out of 5 in the difficulty scale). This is the preferred difficulty level because we want pain education intervention to be difficult enough to challenge participants but not too easy or very difficult. |